Results 21 to 30 of about 12,443,450 (160)

Identification of an apoC-II variant (apoC-IIBethesda) in a kindred with apoC-II deficiency and type I hyperlipoproteinemia.

Journal of Lipid Research, 1988
Apolipoprotein (apo) C-II deficiency is characterized by elevated plasma triglycerides, chylomicrons, and very low density lipoproteins, as well as reduced levels of low density and high density lipoproteins.
D L Sprecher, L Taam, R E Gregg, S S Fojo, D M Wilson, M L Kashyap, H B Brewer, Jr   +6 more
doaj   +1 more source

Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes

Journal of Lipid Research, 1999
Type III hyperlipoproteinemia (HLP) is a genetic disorder characterized by accumulation of remnant lipoproteins in the plasma and development of premature atherosclerosis. Although receptor binding-defective forms of apolipoprotein (apo) E are the common
Robert W. Mahley, Yadong Huang, Stanley C. Rall, Jr.   +2 more
doaj   +1 more source

Premature development of iliac artery stenosis in asymptomatic type II hyperlipoproteinemia.

, 1984
There is conflicting evidence on the relationship between increased low density lipoprotein (LDL) concentration in Type II hyperlipoproteinemia and premature development of peripheral atherosclerosis of the lower limbs.
M Mancini, A Postiglione, F Faccenda, P Rubba, B De Simone, G Riccardi   +5 more
core   +1 more source

HYPERLIPOPROTEINEMIA IN PATIENTS WITH CHRONIC RENAL FAILURE

, 1972
Concentrations of triglycerides and cholesterol in serum and the distribution of plasma lipoprotein fractions have been studied in 25 patients with chronic non‐nephrotic renal failure.
Brøns, Morten, Hørder, Mogens, Christensen, N. C.   +2 more
core   +1 more source

Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 --> Cys) homozygotes is associated with hyperinsulinemia [PDF]

, 2002
Type III hyperlipoproteinemia (HLP) is mainly found in homozygous carriers of apolipoprotein E2 (apoE2, Arg158-->Cys). Only a small percentage ( or = 50 years had significantly higher plasma lipid levels than their counterparts aged < 50 years.
Duijn, C.M. (Cornelia) van, Kastelein, J.J.P. (John), Gevers Leuven, J.A., Hoogerbrugge, N. (Nicoline), Smelt, A.H., Stalenhoef, A.F., Beer, F. (Femke) de, Havekes, L.M.   +7 more
core   +2 more sources

Hepatic cholesterol metabolism in normo- and hyperlipidemic patients with cholesterol gallstones.

Journal of Lipid Research, 1979
In vivo studies have shown abnormalities in cholesterol and bile acid metabolism in primary hyperlipoproteinemia (HLP). The aim of the present investigation was to determine if the increased production of cholesterol in HLP type IV can be attributed to a
J Ahlberg, B Angelin, I Björkhem, K Einarsson, B Leijd   +4 more
doaj   +1 more source

Effectiveness of LDL Apheresis Techniques for Reducing LDL‐C in Familial Hypercholesterolemia: A Systematic Review and Meta‐Analysis

Health Science Reports, Volume 9, Issue 10, October 2026.
ABSTRACT Objective Familial hypercholesterolemia (FH) is a common inherited disorder characterized by markedly elevated low‐density lipoprotein cholesterol (LDL‐C) levels and an increased risk of premature cardiovascular disease. LDL apheresis is an extracorporeal procedure used to remove atherogenic lipoproteins from the circulation and is an ...
Naser Derakhshani, Aziz Rezapour, Seyedeh Narges Pouyan, Ramin Rezapour, Jalal Arabloo, Samira Soleimanpour, Somayeh Afshari, Ali Ariamand   +7 more
wiley   +1 more source

Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study

United European Gastroenterology Journal, Volume 14, Issue 8, October 2026.
ABSTRACT Background Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective.
Marcin Krawczyk, Frank Grünhage, Lisa Schubert, Nektarios Dikopoulos, Jeannette Schwenzer, Marion Muche, Johannes Wiegand, Gisela Felten, Renate Heyne, Patrick Ingiliz, Anna Schmidt, Kerstin Stein, Susanne N. Weber, Heiner Wedemeyer, Stefan Zeuzem, Peter Buggisch, Frank Lammert, Andreas Geier, Wolf Peter Hofmann, Jörn M. Schattenberg   +19 more
wiley   +1 more source

Clinical and Molecular Genetic Risk Factors for Severe Familial Hypercholesterolemia

Journal of Lipid and Atherosclerosis
Objective Familial hypercholesterolemia (FH) is an autosomal dominant disorder associated with a markedly elevated, yet heterogeneous, risk of atherosclerotic cardiovascular disease (ASCVD).
Eun Hoo Rho, Yura Kang, Minjae Yoon, Nak-Hoon Son, Sung Hee Choi, Sang-Hak Lee, Kyong Soo Park, Soo Heon Kwak, n behalf of the Korean Familial Hypercholesterolemia (KFH) Registry Investigators   +8 more
doaj   +1 more source

A Case Report of Familial Chylomicronemia Syndrome With Infantile Onset: One‐Year Follow‐Up on Lipid Profile and Growth Development

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disease caused by a biallelic loss‐of‐function mutation in the lipoprotein lipase (LPL) gene or its cofactors. This case report describes the diagnosis, management, and one‐year follow‐up of an infant with FCS.
Jinyi Liu, Xuanyu Meng, Yi Wu, Guosheng Huang, Shuheng Liang   +4 more
wiley   +1 more source